Beranda › Kanker Paru › New York › New York City
Uji klinis Kanker Paru di New York City, NY
60 studi untuk Kanker Paru mencari peserta di lokasi sekitar New York City (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of ZW251 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Mental Health Care in People With Cancer
Menerima peserta
- Memorial Sloan Kettering Cancer Center, New York
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Menerima pesertaFase 1/2
- Memorial Sloan Kettering (Melanoma/NSCLC), New York
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Menerima pesertaFase 3
- Mount Sinai Chelsea, New York
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
Menerima pesertaFase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Empathic Communication Skills (ECS) Training
Menerima pesertaSukarelawan sehat diterima
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 2
- Memorial Sloan Kettering Hospital, New York
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Menerima pesertaFase 1
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Menerima pesertaFase 3
- NYU Langone's Perlmutter Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Menerima pesertaFase 3
- Memorial Sloan Kettering Cancer Center, New York
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Menerima pesertaFase 2
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Memorial Sloan Kettering Cancer Center, New York
A Registry for People With Lung Cancer
Menerima pesertaStudi observasional
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Menerima pesertaFase 2/3
- NYU Langone Health, New York
- Weill Cornell Medical College, New York
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Menerima pesertaFase 1/2
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Menerima pesertaFase 1/2
- NYU Langone Health Perlmutter Cancer Center, New York
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Menerima pesertaFase 1/2
- Memorial Sloan Kettering Cancer Center, New York
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Menerima pesertaFase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Menerima pesertaFase 1/2
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Memorial Sloan Kettering Cancer Center, New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Menerima pesertaFase 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Menerima pesertaFase 3
- Laura and Isaac Perlmutter Cancer Center, New York
- Manhattan Eye, Ear and Throat Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Menerima pesertaFase 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Menerima pesertaFase 1/2
- Avenzo Therapeutics Recruiting Site, New York
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Menerima pesertaFase 1
- Perlmutter Cancer Center - NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Menerima pesertaFase 3
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Menerima pesertaFase 3
- Cornell University - NewYork-Presbyterian/Weill Cornell Medical Center, New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Menerima pesertaFase 1
- New York Cancer & Blood Specialists, New York
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- New York Proton Center, New York
- Manhattan Eye Ear and Throat Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
- dan 1 lainnya
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Menerima pesertaFase 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- New York Proton Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Lung Cancer Risk
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
Menerima pesertaFase 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Menerima pesertaFase 1
- Xencor Investigative Site, New York
- Xencor Investigative Site, New York
A Study of a Side Effects and Resource Navigation Program for People With Cancer
Menerima peserta
- City College of New York (Data Collection AND Specimen Analysis), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Menerima pesertaFase 1/2
- New York University Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Menerima pesertaFase 2
- New York University Langone Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Menerima pesertaFase 1/2
- NYU Langone Medical Center, New York
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Menerima pesertaFase 1/2
- Weill Medical College of Cornell University, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Menerima pesertaFase 1
- Research Site, New York
- Research Site, New York
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
Menerima pesertaFase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Menerima pesertaFase 1
- NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Menerima pesertaFase 1/2
- Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan-Kettering Cancer Center, New York
- Columbia University, New York
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Menerima pesertaFase 1/2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Brodalumab in the Treatment of Immune-Related Adverse Events
Menerima pesertaFase 1
- Columbia University Irving Medical Center, New York
Lung Cancer Biomarkers and Screening
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- NYU Cancer Institute at New York University Medical Center, New York
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Menerima pesertaFase 1/2
- Laura & Isaac Perlmutter Cancer Center at NYU Langone, New York
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Menerima pesertaFase 2
- Weill Cornell Medicine, New York
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Menerima pesertaFase 1/2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Confocal Laser Endomicroscopy VERification
Menerima peserta
- Montefiore Medical Center, New York
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Menerima pesertaFase 1
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
Menerima pesertaStudi observasional
- Manhattan Eye Ear and Throat Hospital, New York
- Lenox Hill Hospital, New York
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Menerima pesertaFase 1/2
- Weill Cornell Medicine, Cornell University (site 126), New York
Longitudinal Evaluation of Microbial and Host Signatures During Immunotherapy for Lung Cancer
Menerima pesertaStudi observasional
- NYU Langone Health, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Menerima pesertaFase 1/2
- NYU Langone Health, New York
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
Menerima pesertaFase 2
- NYU Langone Health, New York
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
Menerima pesertaStudi observasional
- Icahn School of Medicine at Mount Sinai, New York
Comprehensive Outcomes for After Cancer Health
Menerima pesertaSukarelawan sehat diterima
- Memorial Sloan Kettering Cancer Center, New York
Uji klinis Kanker Paru di kota lain
- Houston, TX78 studi
- Boston, MA62 studi
- Los Angeles, CA45 studi
- Arlington, VA41 studi
- Washington, DC41 studi
- Chicago, IL41 studi
- Nashville, TN40 studi
- Baltimore, MD40 studi
- St. Louis, MO39 studi
- Columbus, OH37 studi
- Philadelphia, PA36 studi
- Seattle, WA33 studi
Studi lain di New York City
- Kanker Payudara136 studi
- Kanker Paru Non-Sel Kecil121 studi
- Kanker (semua jenis)109 studi
- Kanker Prostat103 studi
- Kanker Metastatik93 studi
- Kanker Kolorektal78 studi
- Kanker Ovarium69 studi
- Mieloma Multipel60 studi
- Kanker Pankreas60 studi
- Kanker Endometrium52 studi
- Leukemia Mieloid Akut51 studi
- Gagal Jantung51 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.